Different effects of the β-adrenoceptor antagonists celiprolol and metoprolol on vascular structure and function in long-term type I diabetic rats

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 2, 1999, Pages 193-203

  Olbrich, Antje ^a   Salameh, Aida ^a   Roesen, Peter ^b   Dhein, Stefan ^a,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Celiprolol; Diabetes mellitus; Edothelial dysfunction; Endothelial cell culture; Hypertension; Mesenteric vasculature; Metoprolol

Indexed keywords

ACETYLCHOLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELIPROLOL; GLUCOSE; KETONE; LIPID; METOPROLOL; N(G) NITROARGININE; NITRIC OXIDE; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY MEDIA; ARTERY PERMEABILITY; ARTICLE; BODY WEIGHT; CATTLE; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DRUG EFFECT; ENDOTHELIUM CELL; GLOMERULOSCLEROSIS; HEART MUSCLE CAPILLARY; HEART MUSCLE CELL; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INTRAPERITONEAL DRUG ADMINISTRATION; KETONURIA; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; SWINE; VASCULAR ENDOTHELIUM;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOOD CHEMICAL ANALYSIS; BLOOD VESSELS; CELIPROLOL; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; ENDOTHELIUM, VASCULAR; MALE; MESENTERIC ARTERIES; METOPROLOL; NITRIC OXIDE; RATS; RATS, WISTAR;

EID: 0032935840     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199902000-00004     Document Type: Article

References (62)

1. Heptinstall RH. The kidneys. In: Wright GP, Symmers WSC, Cameron R, eds. Systemic pathology. London: Longmans, 1996: 751-2.
2. Keilani T, Schlueter W, Battle D. Selected aspects of ACE inhibitor therapy for patients with renal disease: impact on proteinuria, lipids and potassium. J Clin Pharmacol 1995;3:87-97.
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;267:C659-78.
4. Rösen P, Rump AFE, Rösen R. Influence of angiotensin-converting enzyme inhibition by fosinopril on myocardial perfusion in streptozotocin-diabetic rats. J Cardiovasc Pharmacol 1996;27:64-70.
5. Olbrich A, Rösen P, Hilgers R-D, Dhein S. Fosinopril improves the nitric oxide dependent regulation of the vascular tone in mesenteric bed of diabetic rats. J Cardiovasc Pharmacol 1996;27:187-94.
6. 2-agonistic component of the partial agonistic activity. Naunyn Schmiedebergs Arch Pharmacol 1986;333:130-8.
7. 2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 1992;346:27-31.
8. Vyssoulis GP, Kouremetis MT, Valioul MA, Michaelides AP, Toutouzas PK. Effect of beta-blockade on exercise capacity in hypertensive subjects: a one-year double-blind study of celiprolol and metoprolol. Cardiovasc Drugs Ther 1995;9:133-9.
9. Wahlefeld AW. In: Bergmeyer HU, ed. Analyse der blutfette. In: Methoden der enzymatischen analyse. 3rd ed. (II). Weinheim: Verlag Chemie, 1974: 1878-82.
10. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum cholesterol with improved lipolytic efficiency. Clin Chem 1983;29:1075-80.
11. Snell FD, Snell CT. Colorimetric methods of analysis. 3rd ed. (III). New York: Van Nostrand, 1953:288-92.
12. Ley K, Pries AR, Gaethgens P. Topological structure of rat mesenteric microvessel networks. Microvasc Res 1986;32:315-32.
13. Müller A, Dhein S. Videoangiometric investigation of microcirculation. In: Cardiovascular and respiratory - in vivo studies. Hugstetten: Biomesstechnik-Verlag, 1991:77-81.
14. G-nitro arginine (L-NOARG): a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilation in vitro. Br J Pharmacol 1990;99:408-12.
15. Salameh A, Schomecker G, Breitkopf K, Dhein S, Klaus W. The effect of the calcium-antagonist nitrendipine on intracellular calcium concentration in endothelial cells. Br J Pharmacol 1996; 118:1899-904.
16. Kelm M, Feelisch M, Spahr R, Piper HM, Noack EA, Schrader J. Quantitative and kinetic characterisation of nitric oxide and EDRF release from cultured endothelial cells. Biochem Biophys Res Commun 1988;154:237-44.
17. 2-adrenoceptors. Biochim Biophys Acta 1993;1178:286-98.
18. Taylor PD, Poston L. The effect of hyperglycaemia on function of rat isolated mesenteric resistance artery. Br J Physiol 1994;113: 801-8.
19. Taylor PD, Graves JE, Poston L. Selective impairment of acetylcholine-mediated endothelium-dependent relaxation in isolated resistance arteries of the streptozotocin-induced diabetic rat. Clin Sci Colch 1995;88:519-24.
20. Taylor PD, Oon BB, Thomas CR, Poston L. Prevention by insulin treatment of endothelial dysfunction but not enhanced noradrenaline-induced contractility in mesenteric resistance arteries from streptozotocin-induced diabetic rats. Br J Pharmacol 1994;111: 35-41.
21. Taylor PD, Wickenden AD, Mirrlees DJ, Poston L. Endothelial function in the isolated perfused mesentery and aortae of rats with streptozotocin-induced diabetes: effect of treatment with the aldose reductase inhibitor, ponalrestat. Br J Pharmacol 1994;111:42-8.
22. Diederich D, Skopec J, Diederich A, Dai F-X. Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals. Am J Physiol 1994;266:H1153-61.
23. Dai F-X, Diederich A, Skopec J, Diederich D. Diabetes-induced endothelial dysfunction in streptozotocin-treated rats: role of prostaglandin endoperoxides and free radicals. J Am Soc Nephrol 1993;4:1327-36.
24. Mayhan WG. Impairment of endothelium-dependent dilatation of the basilar artery during diabetes mellitus. Brain Res 1992; 580:297-302.
25. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992;90:2548-54.
26. McNally PG, Watt PA, Rimmer T, Burden AC, Hearnshaw JR, Thurston H. Impaired contraction and endothelium-dependent relaxation in isolated resistance vessels from patients with insulin-dependent diabetes mellitus. Clin Sci Colch 1994;87:31-6.
27. Saenz de Tejada IS, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989;320:1025-30.
28. Koltai MZ. The effects of prostaglandins and the role of their altered synthesis in diabetes mellitus. In: Nagano M, Dhalla NS, eds. The diabetic heart. New York: Raven Press, 1991:425-37.
29. 2 release in normal and diabetic rats by the antithrombotic compound Bay G 6375. Thromb Res 1980;19:663-70.
30. Salameh A, Hardegen P, Zinn M, Dhein S, Klaus W. Chronic treatment of endothelial cells with high glucose leads to significant changes in intracellular calcium and cell morphology [Abstract]. Naunyn Schmiedebergs Arch Pharmacol 1996;353(4 suppl):R66.
31. Nakamura Y, Horii Y, Nishino T, et al. Immunohistochemical localization of advanced glycosylation products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993;143:1649-56.
32. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med 1994;16:383-91.
33. Rösen P, Ballhausen T, Bloch W, Addicks K. Endothelial relaxation is disturbed by oxidative stress in the diabetic rat heart: influence of tocopherol as antioxidant. Diabetologia 1995;38:1157-68.
34. Pieper GM, Peltier BA. Amelioration by L-arginine of a dysfunctional arginine/nitric oxide pathway in diabetic endothelium. J Cardiovasc Pharmacol 1995;25:397-403.
35. Cameron NE, Cotter MA. Impaired contraction and relaxation in aorta from streptozotocin-diabetic rats: role of polyol pathway. Diabetologia 1992;35:1011-9.
36. Tesfamariam B, Palacino JJ, Weisbrod RM, Cohen RA. Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta. J Cardiovasc Pharmacol 1993;21:205-11.
37. Wu G, Meininger CJ. Impaired arginine metabolism and NO synthesis in coronary endothelial cells of the spontaneously diabetic BB rat. Am J Physiol 1995;269:H1312-8.
38. Factor SM, Sonnenblick EH. The pathogenesis of clinical and experimental cardiomyopathies: recent concepts. Prog Cardiovasc Dis 1995;27:395-120.
39. Fein FS, Strobeck JE, Malhorta A, Scheiner J, Sonnenblick EH. Reversibility of diabetic cardiomyopathy with insulin in rats. Circ Res 1981;49:1251-61.
40. Factor SM, van Hoeven KH, Cho S, Fein FS. Microangiopathy and focal myocardial injury: their role in the development of diabetic cardiomyopathy. In: Nagano M, Dhalla NS, eds. The diabetic heart. New York: Raven Press, 1991:89-101.
41. Dhein S, Tschöpe D, Rösen P, Rösen R, Klaus W, Ziegler D. Defects in the myocardial conduction system of streptozotocin-diabetic rats. In: Ward J, Goto Y, eds. Diabetic neuropathy. Wichester: Wiley, 1990:117-20.
42. Rakusan K. Coronary angiogenesis. In: Claycomb WC, Di Nardo P, eds. Cardiac growth and regeneration. Ann N Y Acad Sci 1995:752:257-66.
43. Yue DK, McLennan SV, Turtle JR. Pathogenesis of diabetic microangiopathy: the roles of endothelial cell and basement membrane abnormalities. Diabetes Med 1992;9:218-23.
44. Pennington SR. G-proteins and diabetes. Nature 1987;327:188-9.
45. 2+ transport in streptozotocin-induced diabetic cardiomyopathy. In: Nagano M, Dhalla NS, eds. The diabetic heart. New York: Raven Press, 1991:219-28.
46. Opie LH, Tansey MJ, Kennelly BM. The heart in diabetes mellitus. Afr Med J 1979;56:207-11.
47. Shanker R, Neeley WE, Dillmann WH. Rapid effects of insulin on in vitro translational activity of specific mRNA in diabetic at heart. Am J Physiol 1986;250:E558-63.
48. Bohlen HG, Hankins KD. Early arteriolar and capillary changes in streptozotocin-induced diabetic rats and intraperitoneal hyperglycaemic rats. Diabetologia 1982;22:344-8.
49. Unthank JL, Bohlen HG. Intestinal microvascular growth during maturation in diabetic juvenile rats. Circ Res 1988;63:429-36.
50. Cooper ME, Rumble J, Komers R, Du HC, Jandeleit K, Chou ST. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes 1994; 43:1221-8.
51. Connors BA, Bohlen HG, Evan AB. Vascular endothelium and smooth muscle remodelling accompanies hypertrophy of intestinal arterioles in streptozotocin diabetic rats. Microvasc Res 1995; 49:340-9.
52. Kritz H, Najemnik C, Irsigler K. P-Rezeptoren-Blockade und Diabetes mellitus: effekt von Celiprolol auf Blutzucker und Insulin-Bedarf bei Typ I- und Typ II-Diabetikern. Arzneimittelforschung 1983;33:72-6.
53. Janka HU, Petschke H, Mehnert H. Der Einfluss einer Betablockertherapie mit Celiprolol auf den Stoffwechsel von insulinbehandelten Diabetikern. Med Klin 1985;80:764-8.
54. Hunninghake DB. Effects of Celiprolol and other antihypertensive agents on serum lipids and lipoproteins. Am Heart J 1991;121:696-701.
55. Sawicki PT, Berger M. Metabolische Wirkungen von β-Rezeptor-blockern. Was ist praktisch wichtig bei der antihypertensiven Therapie? Dtsch Med Wochenschr 1992;117:875-9.
56. 2-selective adrenoceptor antagonist (ICI-118,551). J Cardiovase Pharmacol 1983;5:430-7.
57. DeRubertis FR, Craven PA. Activation of protein kinase C in glomerular cells in diabetes: mechanism and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 1994;43:1-8.
58. Feuerstein GZ, Ruffolo RR Jr. Carvedilol: a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995;16:38-42.
59. Aniya Y, Fong KF, Naito A, Sakanashi M. Antioxidative action of the beta-adrenoceptor antagonist bopindolol and its metabolite 18-502. Jpn J Pharmacol 1995;68:323-9.
60. Johnston GD, Vyssoulis G, Feely J, Holden RD, Radley DR. Effect of celiprolol and metoprolol on lipids, fibrinogen and airways in hyperlipidaemic hypertensives: a randomised double-blind long-term parallel group trial. J Hum Hypertens 1995;9:123-9.
61. Abdeen OA, Taylor BK, Youngblood KL, Printz MP. Peripheral beta adrenergic blockade modifies airpuff startle-induced heart rate responses. J Pharmacol Exp Ther 1995;272:282-9.
62. Tare M, Parkington HC, Coleman HA, Neild TO, Dusting GJ. Hyperpolarization and relaxation of arterial smooth muscle caused by nitric oxide derived from the endothelium. Nature 1990; 346:69-71.